LATANOPROST PFIZER latanoprost 50 microgram/mL eye drops bottle

Quốc gia: Úc

Ngôn ngữ: Tiếng Anh

Nguồn: Department of Health (Therapeutic Goods Administration)

Thành phần hoạt chất:

latanoprost

Sẵn có từ:

Pfizer Australia Pty Ltd

INN (Tên quốc tế):

Latanoprost

Tình trạng ủy quyền:

Registered

Tờ rơi thông tin

LATANOPROST PFIZER
®
_Latanoprost_
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Latanoprost Pfizer. It
does not contain all the available
information. It does not take the
place of talking to your doctor or
pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you using Latanoprost
Pfizer against the benefits it is
expected to have for you.
IF YOU HAVE ANY CONCERNS ABOUT
USING THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
WHAT LATANOPROST
PFIZER IS USED FOR
Latanoprost Pfizer is used to lower
raised pressure in the eye and to treat
glaucoma. Glaucoma is a condition
in which the pressure of fluid in the
eye may be high. However, some
people with glaucoma may have
normal eye pressure.
Glaucoma is usually caused by a
build up of the fluid which flows
through the eye. This build up occurs
because the fluid drains out of your
eye more slowly than it is being
pumped in. Since new fluid continues
to enter the eye, joining the fluid
already there, the pressure continues
to rise. This raised pressure may
damage the back of the eye resulting
in gradual loss of sight. Damage can
progress so slowly that the person is
not aware of this gradual loss of
sight. Sometimes even normal eye
pressure is associated with damage to
the back of the eye.
There are usually no symptoms of
glaucoma. If glaucoma is not treated
it can lead to serious problems,
including total blindness. In fact,
untreated glaucoma is one of the
most common causes of blindness.
_HOW LATANOPROST PFIZER_
_WORKS_
Latanoprost Pfizer belongs to a
family of medicines called
prostaglandin agonists.
It lowers the pressure in the eye by
allowing more fluid to flow out from
within your eye.
Although Latanoprost Pfizer helps
control your glaucoma it does not
cure it. So you must keep using it
until your doctor tells you to stop.
Latanoprost Pfizer is used, either
alone or in combination with other
eye medicines, t

Đặc tính sản phẩm

Version: pfplatne10516
Supersedes: pfplatne10114
Page 1 of 12
PRODUCT INFORMATION
LATANOPROST PFIZER
®
(LATANOPROST)
NAME OF THE MEDICINE
The chemical name of latanoprost is Isopropyl-(Z)-7[(1R,2R,3R,5S)
3,5-dihydroxy-2-
[(3R)-3-hydroxy-5-phenyl-1-pentyl]cyclopentyl]-5-heptenoate, according
to IUPAC.
Its molecular formula is C
26
H
40
O
5
and its molecular weight is 432.58. The CAS
number for latanoprost is 130209-82-4. The chemical structure is as
follows:
OH
OH
OH
COOCH(CH
3
)
2
DESCRIPTION
The active ingredient in LATANOPROST PFIZER is latanoprost, a
prostaglandin F
2

analogue. Latanoprost is a viscous oil which is practically insoluble
in water, freely
soluble in ethanol, ethyl acetate, isopropanol, methanol, acetone and
octanol, and very
soluble in acetonitrile.
Sixty
four
isomers
of
latanoprost
are
possible,
however,
for
LATANOPROST
PFIZER it is purified as a single isomer.
LATANOPROST PFIZER Eye Drops is a sterile, isotonic solution
containing 50
micrograms/mL
of
latanoprost
in
an
aqueous
buffer
solution
of
pH
6.7.
The
excipients
in
LATANOPROST
PFIZER are sodium chloride, sodium phosphate
monobasic monohydrate, sodium phosphate dibasic anhydrous, Water for
Injections
and benzalkonium chloride (0.20 mg/mL) as a preservative agent.
The solution is a clear and colourless liquid, filled in a
polyethylene container.
PHARMACOLOGY
PHARMACODYNAMICS
Latanoprost, a selective prostaglandin F
2

analogue, is a selective prostanoid FP
receptor agonist which reduces the intraocular pressure (IOP) by
increasing the
outflow of aqueous humour. Reduction of the IOP in man starts about
three to four
hours after administration and maximum effect is reached after 8 to 12
hours.
Version: pfplatne10516
Supersedes: pfplatne10114
Page 2 of 12
Pressure reduction is maintained for at least 24 hours. Studies in
animals and man
indicate that the main mechanism of action is increased uveoscleral
outflow, although
some increase in outflow facility (decrease in outflow resistance) has
been reported in
man.
Clinical trials have sh